Hybio Pharmaceutical (SHE:300199) — Market Cap & Net Worth
Market Cap & Net Worth: Hybio Pharmaceutical (300199)
Hybio Pharmaceutical (SHE:300199) has a market capitalization of $2.64 Billion (CN¥18.05 Billion) as of August 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #5228 globally and #897 in its home market, demonstrating a 2.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hybio Pharmaceutical's stock price CN¥20.44 by its total outstanding shares 883241336 (883.24 Million). See Hybio Pharmaceutical capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Hybio Pharmaceutical Market Cap History: 2015 to 2026
Hybio Pharmaceutical's market capitalization history from 2015 to 2026. Data shows change from $3.12 Billion to $2.64 Billion (-0.23% CAGR).
Hybio Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hybio Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.82x
Hybio Pharmaceutical's market cap is 2.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.12 Billion | $768.26 Million | $305.34 Million | 4.06x | 10.21x |
| 2016 | $2.28 Billion | $855.05 Million | $291.92 Million | 2.67x | 7.81x |
| 2017 | $2.08 Billion | $1.25 Billion | $329.72 Million | 1.67x | 6.30x |
| 2018 | $1.21 Billion | $1.26 Billion | -$340.78 Million | 0.95x | N/A |
| 2019 | $749.63 Million | $614.19 Million | -$884.77 Million | 1.22x | N/A |
| 2020 | $859.49 Million | $721.72 Million | -$609.43 Million | 1.19x | N/A |
| 2021 | $1.63 Billion | $735.97 Million | $30.81 Million | 2.21x | 52.90x |
| 2022 | $2.27 Billion | $704.32 Million | -$370.55 Million | 3.23x | N/A |
| 2023 | $1.76 Billion | $431.38 Million | -$513.88 Million | 4.07x | N/A |
| 2024 | $1.67 Billion | $590.20 Million | -$173.65 Million | 2.82x | N/A |
Competitor Companies of 300199 by Market Capitalization
Companies near Hybio Pharmaceutical in the global market cap rankings as of August 4, 2026.
Key companies related to Hybio Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Hybio Pharmaceutical Historical Marketcap From 2015 to 2026
Between 2015 and today, Hybio Pharmaceutical's market cap moved from $3.12 Billion to $ 2.64 Billion, with a yearly change of -0.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.64 Billion | +14.19% |
| 2025 | CN¥2.31 Billion | +38.87% |
| 2024 | CN¥1.67 Billion | -5.08% |
| 2023 | CN¥1.76 Billion | -22.75% |
| 2022 | CN¥2.27 Billion | +39.41% |
| 2021 | CN¥1.63 Billion | +89.62% |
| 2020 | CN¥859.49 Million | +14.66% |
| 2019 | CN¥749.63 Million | -37.90% |
| 2018 | CN¥1.21 Billion | -41.88% |
| 2017 | CN¥2.08 Billion | -8.86% |
| 2016 | CN¥2.28 Billion | -26.90% |
| 2015 | CN¥3.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Hybio Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.64 Billion USD |
| MoneyControl | $2.64 Billion USD |
| MarketWatch | $2.64 Billion USD |
| marketcap.company | $2.64 Billion USD |
| Reuters | $2.64 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more